Even though it is notoriously hard to inhibit transcription factors, elucidation of the mechanisms of action of FOXA1 in TNBC may lead to the identification of druggable targets, as was recently shown in a subset of non-small cell lung cancer cell lines [58]. This evidence concerns the gene FOXA1 and non-small cell lung carcinoma.